Comparison of clinical efficacy of evolocumab and probucol after PCI in patients with ultra-high-risk atherosclerotic cardiovascular disease
- VernacularTitle:依洛尤单抗与普罗布考对超高危动脉粥样硬化心血管疾病患者PCI术后的临床效果对比
- Author:
Yi YUAN
1
;
Na LI
1
;
Haiying SUN
1
;
Jing SUN
1
;
Yongqiang MA
1
;
Yan WU
1
;
Guohong YANG
2
;
Junxiang LIU
1
Author Information
1. Dept. of Cardiology and Critical Care Medicine，Special Medical Center of the Chinese People’s Armed Police Force，Tianjin 300162，China
2. Institute for Cardiovascular Disease Prevention and Control in High- Altitude and Cold Environments，Special Medical Center of the Chinese People’s Armed Police Force，Tianjin 300162，China
- Publication Type:Journal Article
- Keywords:
evolocumab;
probucol;
ultra-high-risk atherosclerotic cardiovascular disease;
percutaneous coronary intervention
- From:
China Pharmacy
2026;37(5):645-649
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy and safety of evolocumab and probucol in patients with ultra-high-risk atherosclerotic cardiovascular disease （ASCVD） following percutaneous coronary intervention （PCI）. METHODS A retrospective analysis was conducted on 156 ultra-high-risk ASCVD patients who underwent PCI in our institution between January 1， 2023 and December 31， 2024. According to the lipid-lowering regimen， the patients were categorized into evolocumab group （ n ＝86） and probucol group （ n ＝70）. Changes in lipid parameters [total cholesterol （TC）， low-density lipoprot ein cholesterol （LDL-C）， high-density lipoprotein cholesterol （HDL-C）， triglycerides， lipoprotein （a）， and lipid goal achievement rate ] ， inflammatory markers [interleukin-6 （IL-6） and C-reactive protein （CRP） ] ， and cardiac function indices （left ventricular ejection fraction， left ventricular end-systolic diameter， left ventricular end-diastolic diameter， and N-terminal pro-B-type natriuretic peptide） were compared between two groups at baseline and after 6 months of treatment. The incidence of adverse clinical events during treatment， including acute myocardial infarction， in-stent restenosis， acute heart failure， cerebral hemorrhage， and stroke， was also evaluated. RESULTS No statistically significant differences were observed between the two groups at baseline （ P ＞0.05）. After 6 months of treatment， both groups demonstrated significant improvements in lipid profiles （except HDL-C） and inflammatory markers compared to those at baseline （ P ＜0.05）. The evolocumab group exhibited greater reductions in TC， LDL-C， IL-6， and CRP， along with a higher lipid target achievement rate， compared with the probucol group （ P ＜0.05）. There were no statistically significant differences in the cardiac function-related indicators before and after treatment between the two groups， nor in the incidence of adverse events during the treatment （ P ＞0.05）. CONCLUSIONS For ultra-high-risk ASCVD patients after PCI， both of the above treatment options are associated with improvements in blood lipid and inflammatory response， with good safety during short-term follow-up. Evolocumab shows superior efficacy in TC， LDL-C and inflammatory markers reduction and lipid target achievement， compared to probucol.
